787563-23-9Relevant academic research and scientific papers
Imidazole-derived agonists for the neurotensin 1 receptor
Hershberger, Paul M.,Hedrick, Michael P.,Peddibhotla, Satyamaheshwar,Mangravita-Novo, Arianna,Gosalia, Palak,Li, Yujie,Gray, Wilson,Vicchiarelli, Michael,Smith, Layton H.,Chung, Thomas D.Y.,Thomas, James B.,Caron, Marc G.,Pinkerton, Anthony B.,Barak, Lawrence S.,Roth, Gregory P.
, p. 262 - 267 (2014)
A scaffold-hop program seeking full agonists of the neurotensin-1 (NTR1) receptor identified the probe molecule ML301 (1) and associated analogs, including its naphthyl analog (14) which exhibited similar properties. Compound 1 showed full agonist behavior (79-93%) with an EC50 of 2.0-4.1 μM against NTR1. Compound 1 also showed good activity in a Ca mobilization FLIPR assay (93% efficacy at 298 nM), consistent with it functioning via the G q coupled pathway, and good selectivity relative to NTR2 and GPR35. In further profiling, 1 showed low potential for promiscuity and good overall pharmacological data. This report describes the discovery, synthesis, and SAR of 1 and associated analogs. Initial in vitro pharmacologic characterization is also presented.
FIVE-MEMBERED HETEROCYCLIC DERIVATIVE
-
Page/Page column 24, (2010/11/08)
The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.
